Copertina

Bradycardic Responses During Thermal Ablation for Hepatocellular Carcinoma: Impact of Procedural Pain Severity and Autonomic Imbalance

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Yasuyuki Komiyama, Masaru Muraoka, Tetsuya Iijima, Leona Osawa, Hitomi Takada, Yuichiro Suzuki, Mitsuaki Sato, Shinichi Takano, Shinya Maekawa, Atsunori Tsuchiya, Nobuyuki Enomoto
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2025
Soggetti:	Hepatology Research
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

TCR Repertoire Analysis During Therapeutic Interventions in Liver Diseases Using Next‐Generation Sequencing
di: Natsuko Nakakuki, et al.
Pubblicazione: (2024)

Rechallenge of Atezolizumab Plus Bevacizumab Therapy in Patients With Unresectable Hepatocellular Carcinoma
di: Yuichiro Suzuki, et al.
Pubblicazione: (2025)

Evaluating Malignant Potential of Gastric Adenomas: The Role of Endoscopic Features and Genetic Alterations
di: Takeshi Ishida, et al.
Pubblicazione: (2025)

Reply to Letter to the Editor: Regarding the “Hepatitis B surface antigen glycan isomer is a predictor of the development of hepatocellular carcinoma during nucleoside/nucleotide analog therapy”
di: Ritsuzo Kozuka, et al.
Pubblicazione: (2024)

Genetic alterations in hepatocellular carcinoma after sustained virological response in relation to the molecular characterization of metabolic diseases
di: Fukiko Kawai‐Kitahata, et al.
Pubblicazione: (2025)

Microwave Thermosphere Ablation Versus Radiofrequency Ablation in Hepatocellular Carcinoma: Optimizing Treatment Strategies for Tumor Size and Malignancy Grade
di: Hideyuki Tamai, et al.
Pubblicazione: (2025)

A Novel Diagnostic Approach for Hepatocellular Carcinoma Using Glycosylated Ferritin
di: Akiyo Ishiguro, et al.
Pubblicazione: (2026)

Ablation‐Based Salvage Strategy at Disease Progression After Initial Disease Control With Atezolizumab/Bevacizumab in Hepatocellular Carcinoma
di: Kazuya Kariyama, et al.
Pubblicazione: (2026)

Validation of Liquid Biopsy Using a Methylated SEPT9 Assay and Integrated Index for Detecting Hepatocellular Carcinoma
di: Issei Saeki, et al.
Pubblicazione: (2025)

Dual Escape From Disulfidptosis and Ferroptosis Drives Highly Aggressive, Hypermetabolic Hepatocellular Carcinoma
di: Junya Mita, et al.
Pubblicazione: (2026)

Clinical Impact of Recurrence Beyond the Milan Criteria After Curative Resection of Hepatocellular Carcinoma
di: Takeshi Terashima, et al.
Pubblicazione: (2025)

Efficacy and Safety of Microwave Ablation in Patients With Hepatocellular Carcinoma With Decompensated Liver Cirrhosis: A Retrospective Study
di: Jihua Xue, et al.
Pubblicazione: (2025)

Clinical Outcomes of Fontan‐Associated Hepatocellular Carcinoma: a Single‐Center Retrospective Study
di: Tomomi Kogiso, et al.
Pubblicazione: (2026)

Safety and Efficacy of Durvalumab Plus Tremelimumab in Older Individuals With Unresectable Hepatocellular Carcinoma: A Multicenter Analysis
di: Tomomitsu Matono, et al.
Pubblicazione: (2025)

Newly established borderline resectable 1 (BR1) category is one of the favorable candidates for selecting the use of multidisciplinary combination therapy in patients with advanced hepatocellular carcinoma treated with systemic therapy
di: Yusuke Kawamura, et al.
Pubblicazione: (2024)

Individualized Prognostication Based on Deep‐Learning Models Using Computed Tomography as an Imaging Biomarker After Hepatocellular Carcinoma Resection
di: Hiroji Shinkawa, et al.
Pubblicazione: (2025)

The Low Platelet Count at the Start of Atezolizumab Plus Bevacizumab Therapy for Unresectable Hepatocellular Carcinoma Predicts Deteriorated Liver Function at the Time of Disease Progression Thereafter: A Multicenter Analysis
di: Ryo Sato, et al.
Pubblicazione: (2025)

Impact of Intrahepatic Tumor Burden on Outcomes in Patients With Hepatocellular Carcinoma With Extrahepatic Metastases Treated With Atezolizumab Plus Bevacizumab
di: Kazunari Tanaka, et al.
Pubblicazione: (2026)

Serum Growth Differentiation Factor 15 Can Be a Novel Biomarker to Predict the Prognosis of Patients With Hepatitis C Virus Cirrhosis After Virus Elimination
di: Yuta Myojin, et al.
Pubblicazione: (2025)

Preventive Effect of Mineralocorticoid Receptor Antagonists Against Proteinuria Induced by Atezolizumab Plus Bevacizumab Therapy in Hepatocellular Carcinoma: A Multicenter Retrospective Study
di: Tomoki Hori, et al.
Pubblicazione: (2026)

Involvement of the ADAMTS13–von Willebrand factor axis in acute kidney injury in mice with liver cirrhosis
di: Masayoshi Takami, et al.
Pubblicazione: (2025)

Tumor Mutational Concordance and Recurrence Timing in Hepatocellular Carcinoma
di: Yuya Miura, et al.
Pubblicazione: (2026)

The Advanced Lung Cancer Inflammation Index as a Prognostic Indicator in Patients With Unresectable Hepatocellular Carcinoma Receiving Atezolizumab and Bevacizumab Therapy
di: Van Khanh Nguyen, et al.
Pubblicazione: (2026)

Utility of Oncological Resectability Criteria in Recurrent Hepatocellular Carcinoma After Hepatectomy
di: Nobuaki Ishihara, et al.
Pubblicazione: (2025)

Significance of Evaluating Tumor Markers in the Oncological Criteria for Resectability in Hepatocellular Carcinoma
di: Yuya Miura, et al.
Pubblicazione: (2025)

Aspirin Use and Hepatocellular Carcinoma Risk
di: Kuan‐Fu Liao, et al.
Pubblicazione: (2025)

Characteristics of diabetes mellitus patients with nonviral chronic liver disease who developed hepatocellular carcinoma
di: Kyo Sasaki, et al.
Pubblicazione: (2024)

Efficacy and Safety of Atezolizumab Plus Bevacizumab Versus Durvalumab Plus Tremelimumab for Unresectable Hepatocellular Carcinoma in Patients With Child–Pugh Class B: A Real‐World Study
di: Hideko Ohama, et al.
Pubblicazione: (2026)

The Risk of Developing Hepatocellular Carcinoma Persists in Chronic Hepatitis B Patients Even After the Long‐Term Administration of Nucleos(t)ide Analogs
di: Kazuhiro Murai, et al.
Pubblicazione: (2025)

Refining Surgical Candidate Selection After Systemic Therapy in Advanced Hepatocellular Carcinoma
di: Jinzhen Huang, et al.
Pubblicazione: (2025)

Lymphocyte‐to‐Monocyte Ratio as a Practical Biomarker for Immunotherapy Response in Hepatocellular Carcinoma
di: Satoshi Tanaka
Pubblicazione: (2025)

Mitochondrial Oxidative Stress in Circulating Leukocytes as a Prognostic Marker in Hepatocellular Carcinoma
di: Víctor Merino, et al.
Pubblicazione: (2025)

Subcutaneous Adipose Tissue Accumulation is Associated With an Improved Prognosis in Patients With Hepatocellular Carcinoma
di: Kenji Imai, et al.
Pubblicazione: (2026)

RECAM‐J 2023—Validation and development of the Japanese version of RECAM for the diagnosis of drug‐induced liver injury
di: Atsushi Tanaka, et al.
Pubblicazione: (2024)

Lenvatinib Versus Atezolizumab Plus Bevacizumab as First‐Line Treatment for Advanced Hepatocellular Carcinoma With a CRAFITY Score of 2: A Multi‐Center Retrospective Study
di: Masayuki Ueno, et al.
Pubblicazione: (2025)

Recent advances in hepatitis E virus research and the Japanese clinical practice guidelines for hepatitis E virus infection
di: Tatsuo Kanda, et al.
Pubblicazione: (2024)

Advancing Gene Mutation Analysis Through Post‐Ablation Liver Tumor Biopsy Specimens
di: Tasuku Nakabori, et al.
Pubblicazione: (2025)

Prognostic Value of PALBI in Patients With Hepatocellular Carcinoma and Concurrent Chronic Kidney Disease: A Nomogram Development
di: Jihye Lim, et al.
Pubblicazione: (2026)

Dual Escape From Ferroptosis and Disulfidptosis Denotes a Hypermetabolic, High‐Risk Subtype of Hepatocellular Carcinoma
di: Tadashi Namisaki, et al.
Pubblicazione: (2026)

Clinical Significance of Anti‐Atezolizumab Antibodies in Patients With Unresectable Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab
di: Keishi Ouchi, et al.
Pubblicazione: (2026)